Heptadecan-9-yl 8-((2-hydroxyethyl) (6-oxo-6-(undecyloxy) hexyl) amino) octanoate)
Has been registered, DMF 038143, CDE F20210000505
Custom synthesis & CMO services are available.
License is required from license holder.
SINOPEG is serving pharmaceutical and medical device companies around the globe, with product presence in various pharmaceutical/device development pipeline (pre-clinical, clinical, and post authorization large scale supply). Our facility is ISO9001 and ISO13485 certified, and is operating according to ICH Q7A guidelines to produce products for pharmaceutical companies.
Please contact us at sales@sinopeg.com for PEG derivatives. Our online catalog or inventory may not listed or have all molecular weights and functional groups, which may be available by custom synthesis. Please contact us at sales@sinopeg.com for quotation and availability.
Reference:
1. Wan J, Wang C, Wang Z, et al. CXCL13 promotes broad immune responses induced by circular RNA vaccines. Proc Natl Acad Sci U S A. 2024;121(44):e2406434121. doi:10.1073/pnas.2406434121
2. Wang L, Wan J, He W, et al. IL-7 promotes mRNA vaccine-induced long-term immunity. J Nanobiotechnology. 2024;22(1):716. Published 2024 Nov 16. doi:10.1186/s12951-024-02993-5
3. Tong H, Ma Z, Yu J, et al. Optimizing Peptide-Conjugated Lipid Nanoparticles for Efficient siRNA Delivery across the Blood-Brain Barrier and Treatment of Glioblastoma Multiforme. ACS Chem Biol. 2025;20(4):942-952. doi:10.1021/acschembio.5c00039
4. Shao X, Liu L, Weng C, et al. Leveraging an mRNA Platform for the Development of Vaccines Against Egg Allergy. Vaccines (Basel). 2025;13(5):448. Published 2025 Apr 24. doi:10.3390/vaccines13050448
